Latest news with #KwalityPharmaceuticals
Business Standard
14 hours ago
- Business
- Business Standard
Kwality Pharma secures regulatory approval for anti-cancer drug Bleomycin in Mexico
Kwality Pharmaceuticals announced that it has received registration for Bleomycin 15 IU in Mexico for sale and distribution. According to an exchange filing, Bleomycin is a widely used anti-cancer medicine, effective in the treatment of Hodgkins lymphoma, testicular cancer, and certain squamous cell carcinomas. This approval further strengthens our expansion into highly regulated markets, reinforcing our commitment to delivering quality oncology products globally. The projected business potential is approximately $1 million in the first year, and supplies are expected to commence before the end of Q2 FY26. The company stated that it remains committed to expanding access to high-quality medicines across global markets. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products. The company's consolidated net profit surged 42.7% to Rs 11.93 crore on 39.2% rise in revenue from operations to Rs 111.48 crore in Q1 FY26 over Q1 FY25. The counter slipped 3.37% to Rs 1,033.05 on the BSE.
Business Upturn
18 hours ago
- Business
- Business Upturn
Kwality Pharma receives product registration for Bleomycin 15 IU per vial in Mexico
Kwality Pharmaceuticals Ltd has announced that it has received registration approval for Bleomycin 15 IU in Mexico, enabling the company to begin sales and distribution in the region. Bleomycin is a widely prescribed oncology medicine, used in the treatment of Hodgkin's lymphoma, testicular cancer, and certain squamous cell carcinomas. The approval marks a significant milestone in Kwality Pharmaceuticals' strategy to expand into highly regulated international markets. With this registration, the company is further reinforcing its global footprint in the oncology segment, offering patients access to advanced and affordable cancer treatments. According to the company, the business potential in Mexico is projected to be around USD 1 million in the first year, with supplies scheduled to commence before the end of Q2 FY26. Highlighting its commitment, Kwality Pharmaceuticals stated that it will continue to expand its oncology portfolio across international markets to make high-quality medicines more accessible worldwide. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
11-08-2025
- Business
- Business Standard
Kwality Pharmaceuticals consolidated net profit rises 42.70% in the June 2025 quarter
Sales rise 39.21% to Rs 111.48 crore Net profit of Kwality Pharmaceuticals rose 42.70% to Rs 11.93 crore in the quarter ended June 2025 as against Rs 8.36 crore during the previous quarter ended June 2024. Sales rose 39.21% to Rs 111.48 crore in the quarter ended June 2025 as against Rs 80.08 crore during the previous quarter ended June 2024. Particulars Quarter Ended Jun. 2025 Jun. 2024 % Var. Sales 111.4880.08 39 OPM % 21.6821.65 - PBDT 21.7915.14 44 PBT 17.0311.12 53 NP 11.938.36 43
Business Standard
20-05-2025
- Business
- Business Standard
Kwality Pharma spurts on strong Q4 numbers
Kwality Pharmaceuticals surged 15.69% to Rs 955.30 after the company's adjusted consolidated net profit rose 49.23% to Rs 14.49 crore while net sales rose 25.77% to Rs 115.68 crore in Q4 March 2025 over Q4 March 2024. Sequentially, the company's consolidated net profit surged 69.87% while net sales jumped 37.05% in Q4 FY25 over Q3 FY25. Profit before tax and exceptional items stood at Rs 19.07 crore in Q4 FY25, up 45.80% year-on-year and up 67.43% QoQ. The company reported one time expense of Rs 7.09 crore in Q4 March 2024. For the full year, adjusted net profit rose 36.99% to Rs 39.85 crore while net sales increased 20.52% to Rs 370.20 crore in the year ended March 2025 over the year ended March 2024. Profit before tax and exceptional items rose 42% year-on-year to Rs 54.14 crore in FY25 over FY24. The company's net cash from operating activities stood at Rs 52.72 crore in FY25, higher than Rs 42.98 crore in FY24. Kwality Pharmaceuticals is engaged in the business of manufacturing & trading in pharmaceuticals & allied products.
Business Standard
20-05-2025
- Business
- Business Standard
Kwality Pharmaceuticals consolidated net profit rises 232.34% in the March 2025 quarter
Sales rise 25.77% to Rs 115.68 crore Net profit of Kwality Pharmaceuticals rose 232.34% to Rs 14.49 crore in the quarter ended March 2025 as against Rs 4.36 crore during the previous quarter ended March 2024. Sales rose 25.77% to Rs 115.68 crore in the quarter ended March 2025 as against Rs 91.98 crore during the previous quarter ended March 2024. For the full year,net profit rose 67.44% to Rs 39.85 crore in the year ended March 2025 as against Rs 23.80 crore during the previous year ended March 2024. Sales rose 20.52% to Rs 370.20 crore in the year ended March 2025 as against Rs 307.17 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 115.6891.98 26 370.20307.17 21 OPM % 22.3722.43 - 21.7221.59 - PBDT 24.1618.15 33 72.4357.76 25 PBT 19.0713.08 46 54.1438.20 42 NP 14.494.36 232 39.8523.80 67
